ViRexx Medical Corp.
TSX : VIR

ViRexx Medical Corp.

June 28, 2005 19:03 ET

ViRexx Announces Transfer Of Warrants

EDMONTON, ALBERTA--(CCNMatthews - June 28, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that the TSX has consented to the transfer of 671,875 share purchase warrants ("Warrants") from insiders of ViRexx to non-insiders. These Warrants comprised a part of a private placement that closed on January 2, 2004. The Warrants entitle the holder to purchase one additional common share of the Corporation at a price of $1.00 per common share. After the transference of the Warrants, the Warrant expiry date will be extended from July 7, 2005 to October 14, 2005.

The insiders who have transferred their warrants have not derived nor will derive compensation for these transfers.

About ViRexx Medical Corp. (www.virexx.com)

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C and solid tumors.

ViRexx's lead product, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of a Phase III clinical trial funded by ViRexx's licensing partner United Therapeutics Corporation.



THE TSX HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION CONTAINED HEREIN

Contact Information

  • ViRexx Medical Corp.
    Rob Salmon
    Chief Financial Officer
    (780) 989-6708
    (780) 436-0068 (FAX)
    rsalmon@virexx.com
    or
    The Equicom Group Inc.
    Ross Marshall
    Investor Relations
    (800) 385 5451 ext. 238
    (416) 815-0080 (FAX)
    rmarshall@equicomgroup.com
    or
    Lippert/Heilshorn & Associates Inc.
    Kim Golodetz
    Investor Relations
    (212) 838 -3777
    (212) 838 -4568 (FAX)
    kgolodetz@lhai.com